Narcolepsy

This trial tests whether a low-sodium form of oxybate, called XYWAV, can reduce daytime sleepiness and improve daily function in adults aged 18 to 75 with idiopathic hypersomnia or narcolepsy. Participants take the oral solution at night, with doses adjusted to their needs, and r…

This study tests whether clarithromycin, an antibiotic, can reduce excessive daytime sleepiness in people with narcolepsy or idiopathic hypersomnia. Participants receive either clarithromycin or a placebo for 14 days. Researchers will measure changes in sleepiness, brain activity…

This study involved 155 adults with narcolepsy who were already taking a high-sodium oxybate medication. They switched to Xywav, a low-sodium version, to see if their blood pressure would improve. The goal was to provide doctors and patients with useful information about the impa…

This study compares a new mass spectrometry technique to the standard radioimmunoassay for measuring orexin-A levels in cerebrospinal fluid. Orexin-A is a key brain chemical that is low in people with type 1 narcolepsy. The study involves 117 people with excessive daytime sleepin…

This study tests two behavioral therapies—imagery rehearsal therapy (IRT) and targeted dream control (TDC)—to reduce nightmares in adults with narcolepsy. Participants attend therapy sessions, keep a daily sleep log, and complete questionnaires. Some Chicago-area participants als…

This Phase 2 trial tested AXS-12 (reboxetine) in 21 adults with narcolepsy and cataplexy. Participants received either the drug or a placebo for three weeks, then switched. The goal was to see if AXS-12 could reduce weekly cataplexy attacks and improve excessive daytime sleepines…

This study tested a new medicine called ALKS 2680 in 92 adults with narcolepsy type 1, a condition that causes severe daytime sleepiness and sudden muscle weakness (cataplexy). Participants stopped their usual narcolepsy medications and received either ALKS 2680 or a placebo for …

This study tested a six-session behavioral therapy that teaches people with narcolepsy type 1 how to become aware during dreams (lucid dreaming) and control frightening images. Ninety-eight adults took part, with half receiving the therapy and half getting standard care. The goal…

This study tested an experimental drug called AXS-12 (reboxetine) in 90 people with narcolepsy who experience cataplexy (sudden muscle weakness) and excessive daytime sleepiness. Participants took either the drug or a placebo twice daily for several weeks. The main goal was to se…

This phase 2 study tested an experimental drug called ALKS 2680 in 93 adults with narcolepsy type 2, a condition causing severe daytime sleepiness. Participants took either the drug or a placebo daily to see if it safely improved their ability to stay awake. The trial is now comp…

This study followed 71 adults with narcolepsy who started taking LUMRYZ, a medication for excessive daytime sleepiness. Over 4 months, participants filled out questionnaires about their symptoms, how they felt about the drug, and their quality of life. The goal was to see if LUMR…

This early-phase study tested a new slow-release form of pitolisant (HBS-201) in 46 adults with narcolepsy. The goal was to see if starting at a full dose is tolerable. Participants took the drug for 14 days, and researchers tracked side effects and dropouts.

This study looked at the long-term safety and effectiveness of a drug called AXS-12 for people with narcolepsy who also have sudden muscle weakness (cataplexy) and severe daytime sleepiness. 68 people who had already completed an earlier study took AXS-12 and were monitored for s…

This study tested a new once-nightly medication called FT218 for people with narcolepsy who experience excessive daytime sleepiness and sudden muscle weakness (cataplexy). It included 184 participants, some already on a twice-nightly medication and some new to treatment. The goal…

This study looked at 103 adults with narcolepsy or obstructive sleep apnea to see if anxiety, social, or work factors affect their ability to stay awake during a standard test. Participants filled out an anxiety questionnaire before the test. The goal is to better understand why …

This study looked at how the drug modafinil affects driving ability in 27 people with narcolepsy or hypersomnia. Participants took modafinil or a placebo for five days, then completed both simulated and real driving tests. The goal was to see if the drug improves alertness and re…

This study looked at 24 children (ages 6-17) with narcolepsy or hypersomnia to see if changes in their metabolism explain why they often gain weight and become obese. Researchers measured energy use at home and in the hospital using activity trackers. The goal was to understand t…